Replies to post #2859 on Antares Pharma, Inc. (ATRS)

[Bio_pete]

Silvrmoon, the whole fight with the epi-pen was to get a product approved which is interchangeable with PFE. If you have a scrip for the epi-pen then your pharmacy will fill the order with whatever drug they secured at the lowest price.

Pricing plays a bigger part on sales once its approved then having a prettier package so I don't understand their statement.

[jab91252]

silvrmoon, I assume that the improvements and innovation comment refers to the existing pen. I'd have to go back and check the litigation documents for the exact wording, but I recall during talks before District Court Judge Sleet between both sides of legal counsel, something was mentioned about pending revision or another version. In fact, it led me at one point to think that Antares had two pens in the mix. It leads me to believe that after FDA approval and the green light from the DOJ, that they will be "tweaking" the existing pen as opposed to a brand new pen from someone else or TEVA's own in-house shop.

bio-pete, let's argue that TEVA tries to shake off Antares and go with a "new" pen design - wouldn't that trigger another submittal to the FDA - start from scratch again? From that pdf they used during the recent presentation, it looks like they are trying to portray themselves in a more entrepreneurial fashion - more nimble - but if they are going to go after markets like Antares currently is, I believe Antares is ahead of the game. But who knows what it all means. Maybe they are grooming themselves for the grooming of Antares.

My two cents for this bone chilling day!